The American journal of medicine
-
In 2019, the US Food and Drug Administration (FDA) approved 48 novel drugs. Thirty of the 48 (62.5%) novel drug approvals were reviewed and approved through an expedited review pathway while 20 of the 48 (41.7%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the FDA in 2019.
-
Randomized Controlled Trial
Financial Incentives for Smoking Cessation in Hospitalized Patients: A Randomized Clinical Trial.
Financial incentives for smoking cessation and use of evidence-based therapy may increase quitting rates and reduce health and economic disparities. ⋯ Rates of bioconfirmed smoking cessation were higher among hospitalized patients randomized to financial incentives compared to usual care alone, but the difference was not significant. Considering the frequency of low payouts and the importance of assistance for successful quitting, future studies should explore the effectiveness of financial incentives sufficiently large to overcome barriers to evidence-based therapy.